“The team at the National Tuberculosis Program are in love with the system and they are proud of the solution.”
— Dr. Samuel Kinyanjui, COP TB-ARC, Kenya
Accounting for every diagnosis.
On average, treatment for each patient with TB costs between $250 to $650 and takes 6 to 9 months for a cure. For a single patient with MDR TB, treatment can cost between $1,200 to $5,000, lasts for two years and only about 50-60% are cured. Containment of TB assumes that each positive patient is found and effectively treated in a timely manner to stop the spread of disease. But if a country has a loss to follow-up rate of 15-30%? Let’s imagine Country X has 50,000 positive TB cases. But only 35,000 of those patients begin treatment and the rest are lost to follow-up. The 15,000 patients without treatment may sicken further and be at increased risk of spreading disease. How many secondary transmissions would those 15,000 patients further infect? The WHO states people with active TB can infect 5-15 other people through close contact over the course of a year. With a digitized connected diagnostic system, the patients typically lost to follow-up could be accounted for. With less secondary transmissions, what is the effectiveness of a connected diagnostics system in terms of QALYs saved and DALYs averted? What are the healthcare costs of providing connected TB diagnostics?
Below you will find a list of resources where you can learn more about our technology and how it's having a disruptive impact on Global Health programs worldwide.
Click graphics to view complete research document or presentation.
SystemOne White Paper
“A manufacturer-agnostic and disease-agnostic solution makes sense. At SystemOne, we focus exclusively on connectivity, connecting any device for any disease, routing data to the right people at the right time and ensuring that benefits and cost savings spread through the health system.”
In 2014, a small study in Nigeria showed that only 50% of the MDR-TB patients diagnosed across 35 GeneXpert testing sites were being placed onto treatment. However, when GxAlert* was introduced and used appropriately, this number increased to 85% due to the improved availability, reliability, and timeliness of results to facilities, state program managers, and program enrollments officers1.
TB exerts a major economic burden on countries. By extrapolating this data to national GeneXpert testing numbers, we can make some general assumptions regarding the potential cost savings GxAlert* can provide in a high TB burden country.
In 2015, Nigeria reported 52,219 GeneXpert results with a 22.5% TB positivity rate2. Based on baseline data, we can assume that without GxAlert*, only 50% of these patients would have been placed onto life-saving treatment. However, with GxAlert*, we can safely assume that up to 85% could have been placed onto treatment. The difference in patient numbers placed onto treatment, with and without GxAlert*, is 4112 people. We know that, on average, the non-health GDP loss per TB death in Africa is estimated at $67,0003. Thus, if we assume a conservative 50% mortality rate for the 4112 patients who would not have been placed onto treatment, this results in an estimated $137,760,249 in gross GDP losses for the country. Said in another way, GxAlert* had the potential in 2015, to account for an economic savings of $137,760,249.
Papua New Guinea
Click thumbnail to view PDF
August 2022: Open standard is the new open source
The shift in stance to requiring open standards over open source is a promising new opportunity to accelerate digital interventions in Global Health while maintaining the historical investment in existing systems.
November 2020: Driving the usage of tuberculosis diagnostic data through capacity building in low- and middle-income countries
Connectivity platforms collect a wealth of data from connected GeneXpert instruments, with the potential to provide valuable insights into the burden of disease and effectiveness of tuberculosis programmes.
July 2020 | Evaluation of a mobile application to support HIV self-testing in Johannesburg, South Africa
Human immunodeficiency virus self-testing (HIVST) reduces barriers associated with facility-based testing; however, no formal mechanism exists for users to self-report results or link to care. The Aspect™ HIVST mobile application (app) was developed for use in South Africa.
Sept 2019 | Impact of GxAlert* on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papau New Guinea
Oblective: To determine if there were differences in pre-treatment attrition, the time to treatment initiation and patient outcomes in the 12 months pre- and post-introduction of GxAlert* for RR-TB patients. Click thumbnail to download PDF or click HERE to view on NCBI website
August 2019 | Journal of Clinical Tuberculosis and Other Mycobacterial Diseases:
Feasibility of a short message service (SMS) intervention to deliver tuberculosis testing results in peri-urban and rural Uganda
December 2018 | African Journal of Laboratory Medicine:
The Role of Connected Diagnostics in Strengthening Regional, National and Continental African Disease Surveillance
September 2018 | Technical Brief from MSH, USAID, IRD and ChallengeTB:
GxAlert* for Real-time Management and Strengthening of Remote GeneXpert Network in Bangladesh
July 2018 | Expert Review of Molecular Diagnostics:
Racing for results: lessons learnt in improving the efficiency of HIV viral load and early infant diagnosis result delivery from laboratory to clinic.
April 2018 | Expert Review of Molecular Diagnostics: The impact of digital technologies on point of care diagnostics in resource limited settings.
March 2018 | International Union Against TB & Lung Disease: Unsuccessful Xpert® MTB/RIF results: the Nigerian experience
February 2018 | BMC Research Notes:
Assessment of GeneXpert GxAlert* platform for multi-drug resistant tuberculosis diagnosis and patients’ linkage to care in Tanzania
2016 | Masters Thesis: Effects of GeneXpert MTB/RIF Testing and GxAlert* eHealth Platforms on MDR-TB Diagnosis and Linkage to Care in Sofala Province, Mozambique
October 2016 Remote monitoring of Xpert MTB/RIF testing in Mozambique: results of programmatic implementation of GxAlert*
July 2016 | ERJ Express Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
March 2016 | The Union Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination.
2016: GLI Quick Guide to TB Diagnostics Connectivity Solutions
2015 Implementing rapid testing for tuberculosis in Mozambique
September 2014 | Moses Joloba Introduction of GxAlert* in Uganda
July 2017 | AIDSFree Webinar:SystemOne -Supporting EID & VL Scale Up
July 2017 | USAID: History of Use of GxAlert* in Nigeria
December 2016 | ASLM: Importance of Quality Systems and Connectivity
December 2016 | ASLM:Connectivity Needs for Improved Patient Care
December 2015 | Union Conference: GxAlert* SMS Improves Patient Enrollment
July 2016 | Cracking the Nut Health Conference: Cost Effective Technology for TB
October 2016 | Union Conference: On the ground experiences and challenges of connected diagnostics GxAlert*
April 2013 | GLI Partners Meeting: Faster Response to MDR-TB Through GxAlert*
March 2018 | CROI: Reducing Time for HIV Viral Load Result Delivery to Antiretroviral Treatment Facilities in Malawi.
December 2016 | ASLM: Staying in Control of Lab Data in a World of Connected Diagnostics
December 2016 | ASLM:Continuous Quality Improvement (CQI) Through Connected Diagnostics
December 2016 | ASLM: Using Connected Diagnostics to Implement the New WHO Shorter MDR Treatment Regimen
October 2016 Cost Effective Technology (GxAlert*) Improves Drug-Resistance TB Response in Nigeria
*GxAlert is not associated with Cepheid nor Cepheid instrument systems, including GeneXpert® instruments.